Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH.
Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years' experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient's clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0-54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.
Kizaki
Masahiro
M
Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. makizaki@saitama-med.ac.jp.
Okamoto
Shinichiro
S
Division of Hematology, Keio University School of Medicine, Tokyo, Japan.
Tauchi
Tetsuzo
T
First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
Tanaka
Hideo
H
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Tanimoto
Mitsune
M
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Inokuchi
Koiti
K
Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Murayama
Tohru
T
Hematology Division, Department of Medicine, Hyogo Cancer Center, Hyogo, Japan.
Saburi
Yoshio
Y
Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
Hino
Masayuki
M
Clinical Hematology and Clinical Diagnosis, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Tsudo
Mitsuru
M
Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan.
Shimomura
Taizo
T
Department of Hematology, NTT Japan Kyushu Hospital, Kumamoto, Japan.
Isobe
Yasushi
Y
Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D005260:Female; D006405:Hematology; D006801:Humans; D000068877:Imatinib Mesylate; D020407:Internet; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012042:Registries; D012955:Societies, Medical; D014584:User-Computer Interface
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate